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Flow cytometry
Flow cytometry was used to assess CD73 protein surface expression. Briefly, cultured HUVEC and HPMEC were trypsinized for 0.5 to 1 min. After reaction of trypsin was stopped with serum, cells were harvested and cell pellets washed with PBS, followed by fixation with 2 % paraformaldehyde (Sigma) for 10 min on ice. After a blocking step with 10 % normal serum (PAA), the cells were incubated with primary antibodies (mouse anti-CD73 IE9, Santa Cruz) at 4°C overnight. Primary antibodies were detected with a respective secondary antibody (anti-mouse Alexa 488, Santa Cruz). Measurements were performed in a BD FACS Calibur TM . The results were quantified by Win MDI 2.9 software with gating procedure.
Protein determination and western blot
To detect CD73, CD39, caveolin-1 and annexin-2 expression, samples were collected directly after enzymatic assay by adding Tris/HCl pH 6.9 buffer. Samples were then immediately stored at -20°C. Protein concentration in the samples was determined by both the black amido protein assay and the rotinanoquant assay (Carl Roth, Germany). Protein expression was quantified with western blot. Briefly, equal amounts (20-30 µg) of protein were loaded on 4 to 12 % polyacrylamide gels (Bio Rad Laboratories GmbH, Germany). After electrophoretic separation the proteins were transferred onto nitrocellulose membrane (Amersham Biosciences) following standard procedures. The membrane was then blocked with 5 % skim milk. The membranes were incubated in respective primary antibodies to detect CD73 (1:200, Santa Cruz Biotechnology), CD39 (1:200, Santa Cruz), Cav-1 (1:5000, rabbit, BD Biosciences), annexin-2 (1:2000, rabbit, Santa Cruz). Amounts of target proteins was normalised to α-tubulin and β-actin (both 1:1000, Sigma). Secondary antibodies used were donkey anti-goat (1:2000, Dianova, Hamburg, Germany), goat antimouse (1:1000, Dianova) and goat anti-rabbit (1:1000, Dianova). Protein bands were quantified using an Alias 3000 Reader. Blot images were quantified densitometrically using Image J software.
Real time Polymerase Chain Reaction
From HPMEC incubated with DHA for 36 and 48 hours RNA was isolated using the RNeasy Mini Kit (Qiagen NV, The Netherlands). RT-PCR was performed by standard procedures using the following primers: 1) ecto-5′-nucleotidase/CD73: sense 5' GAT CGA GCC ACT CCT CAA A 3′; antisense 5′ GCC CAT CAT CAG AAG TGA C 3′; 2) GAPDH: sense 5′CAA AGT TGT CAT GGATGA CC3′; antisense 5′CCA TGG AGA AGG CTG GGG3′. Thermal cycling conditions were done as follows: first step, 94°C for 15 min; the ensuing 40 cycles were 95°C for 20 s, 58°C for 30 s and 72°C for 30 s.
HPLC assessment of adenine nucleotides and adenosine
Measurement of etheno(ε)-labelled adenine nucleotides and adenosine. CD73 activity was determined by measuring the conversion of the substrate ε-AMP (Sigma) to ε-adenosine (ε-Ado) using fluorescence HPLC as described before [19] . The kinetic of ε-AMP conversion to ε-Ado was plotted and the time point of 50 % conversion of ε-AMP to ε-Ado was expressed as t 50 value. For statistical analysis, t 50 values in the treatment groups were normalized to their respective controls treated in parallel. CD39 activity was Thom/Wendel/Deussen: DHA and Extracellular Adenine Nucleotide Metabolism Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry measured similarly to CD73 activity, however, ε-ATP (Molecular Probes, Darmstadt, Germany) and ε-ADP (Sigma), rather than ε-AMP, were added as substrates. Measurement of native adenine nucleotides and adenosine. HUVEC and HPMEC cultured and incubated with DHA in serum culture medium (48 h) were washed once with PBS and 2 ml incubation buffer were added. Supernatant (500 µl) was collected after 0, 16 and 32 min of incubation, respectively, immediately frozen in liquid nitrogen and stored at -80 o C until freeze-drying. The residue was redissolved in 143 µl of ultra pure water. For quantification of native adenine compounds a derivatization procedure to etheno(ε)-compounds was used as described [19] . HPLC measurements were performed as reported [20] . Identification and quantification of ε-adenosine and ε-adenine nucleotides were done using external standards.
ATP measurement by luminometry
Cellular native ATP release was measured using an ATP-time stable determination kit (Proteinkinase, Biaffin GmbH & Co KG, Kassel, Germany) which is based on luciferase activity. The fluorescence signal was measured in a luminometer as a function of time and the ATP concentration quantified from the area under the curve using external ATP standards (Sigma) as reference. The ATP release of DHA treated cells was normalized to that of control experiments performed in parallel.
Statistical analysis
Statistical analysis was performed using SPSS for Windows version 15.0. Data were expressed as mean ± SE. Differences of mean values between two groups were analysed by Student's t test. When more than two groups were compared, statistical analysis was performed by a one-way ANOVA followed by post hoc test. A p-value < 0.05 was considered to indicate a statistically significant difference.
Results

DHA up-regulates CD73 protein level
To determine the effects of DHA on CD73 protein level we quantified CD73 surface expression by flow cytometry for both HPMEC and HUVEC (Fig. 1A) . After 48 h DHA treatment CD73 protein surface content increased dose-dependently in both cell types. At 50 µmol/l DHA the increase of CD73 expression was 28±7 % (HPMEC) and 23±6 % (HUVEC) as compared to respective controls (p<0.05, n=6-8). A representative histogram of FL1 fluorescence labelling of CD73 is provided in Fig. 1B . DHA did not have any cytotoxic effect in HUVEC and HPMEC as revealed by MTT assay and LDH release (data not shown). The enhanced CD73 cell surface content indicated by flow cytometry was paralleled by a similar increase in whole cell CD73 protein level. Cellular CD73 protein content increased by 41±11 % and 48±10 % in HPMEC and HUVEC, respectively, in response to 50 µmol/l DHA for 48 hours (p<0.05, n=5-6, Fig. 1C and 1D) .
Recently, DHA as well as some other fatty acids e.g eicosapentaenoic acid and arachidonic acid have been described as potential ligands of the PPAR family including PPAR-γ [21] . Because DHA had no effect on CD73 mRNA level (Fig. 1E) , we evaluated whether DHA via the PPAR-γ pathway may directly regulate some unknown genes which play a role in CD73 expression and enzyme activity. However, application of GW9962 for 72 h had no effect on both CD73 activity (data not shown) and CD73 protein level (Fig. 1F ). This suggests that DHA regulated CD73 independent of the PPAR-γ pathway.
Modulation of lipid raft compositions on CD73 enzymatic activity
As CD73 is known to be located in lipid rafts one may assume that modulation of the lipid membrane composition such as presence of cholesterol or caveolin-1 (cav-1) may modify CD73 activity or CD73 protein expression. We performed experiments in which the cholesterol content in the lipid raft was depleted by filipin ( Fig. 2A ) and beta-methylcyclodextrin (MCD) treatment (Fig. 2B) . In further experiments administration of MCD-cholesterol complex was used to enrich the membrane cholesterol content (Fig. 2B ). However, both displacement and enrichment of cholesterol level had no effect on CD73 activity. In agreement with these results MCD did not have a significant effect on CD73 expression stimulated with DHA ( Fig. 2C) . Hence, we concluded that membrane cholesterol content did not play a major role on regulation of CD73 expression in response to DHA.
In addition, the effect of DHA on cav-1 protein expression was examined (Fig. 2D) . Although minor fluctuations of membrane Cav-1 expression were noted, these fluctuations appeared transient and no significant effect of DHA on cav-1 level could be objectified. Thus, increased expression of CD73 due to DHA treatment was not associated with changes of cav-1 expression. Similar results were observed with HUVEC (data not shown). 
Effects of DHA on CD73 enzymatic activity
To test whether the change in CD73 expression results in a change of enzyme activity conversion of ε-AMP to ε-Ado was measured in both, membrane fraction and cytosolic fraction, after DHA treatment for 48 h (Fig. 3A) . ε-AMP hydrolysis was about two-fold higher in the cell membrane fraction compared to the cytosolic fraction (p<0.001). Upon DHA treatment ε-AMP hydrolysis was accelerated, indicated by decreased t 50 (25±4 %). This effect was restricted to the enzyme activity of the membrane fraction (p<0.005). The results match with those obtained on CD73 protein content (Fig. 3B) . CD73 protein content in the membrane fraction was 3-fold higher than that in the cytosolic fraction. DHA selectively elevated CD73 protein content by 50±15 % in the membrane fraction. Thus, increased membrane CD73 protein content (Fig. 3B) was associated with increased enzyme activity (Fig. 3A) .
Despite an enhanced membrane CD73 protein content in intact HUVEC and HPMEC DHA treatment resulted in prolonged ε-AMP degradation (increase of t 50 16±2 % and 26±10 %, Fig. 3C ). Thus, conversion of extracellular ε-AMP to ε-Ado was slowed down on the whole cell level. Addition of the alkaline phosphatase inhibitor levamisole did not significantly affect hydrolysis rate of extracellular ε-AMP in response to DHA (Fig. 3D) . In contrast, single inhibition of CD73 by its specific inhibitor alpha-beta-methylene-ADP (AOPCP) profoundly inhibited ε-AMP hydrolysis (Fig. 3E) . Thus, in contrast to CD73 alkaline phosphatase is unimportant for AMP hydrolysis in isolated human endothelial cells.
Effects of DHA on CD39
Following DHA treatment ADPase (NTPDase1 or CD39) activity significantly decreased (p<0.05) while ATPase activity remained unchanged (although there was a clear trend Fig. 4A ). The decreased CD39 enzymatic activity was paralleled by a 25±8.5 % decrease of CD39 protein expression (p<0.05, Fig. 4B ). The functional importance of CD39 activity was addressed using the inhibitor ARL-67156 (10 μmol/l), which markedly decreased ε-ADP conversion (ADPase activity) in both DHA treated and DHA untreated groups (Fig. 4C ). For the identical experimental conditions ε-ATP conversion rate (ATPase activity) showed a smaller effect (Fig. 4D) . Potential cross-talk between CD39, alkaline phosphatase and CD73 was studied using ARL-67156 as an inhibitor of CD39 and levamisole as an inhibitor of alkaline phosphatase. Single treatment with levamisole did not have any significant effect on extracellular ε-AMP hydrolysis in both, DHA untreated and DHA treated, HPMEC (Fig. 4E) . In contrast, single treatment with ARL-67156 as well as combined treatment with ARL-67156 plus levamisole reduced extracellular ε-AMP conversion at baseline conditions (without DHA) as well as in presence of DHA (Fig. 4E) . Similar results were observed in HUVEC in response to DHA treatment (Fig. 4F ). This suggests that accumulation of extracellular ATP or ADP blunts CD73 activity in intact cells after DHA treatment.
ATP release from endothelial cells treated with DHA
Following treatment of HUVEC and HPMEC with DHA the ATP concentration in the supernatant was largely increased 5.5±0.9-fold and 2.9±0.2-fold, respectively ( Fig. 5A and B) . To assess that increased ATP release was not due to cell damage, we measured LDH release in parallel which did not change (data not shown). The different native adenine nucleotide fractions were assessed in the supernatant of HPMEC kept in incubation buffer for up to 32 min after a buffer change. The total extracellular nucleotide concentration increased 2.5-fold in the DHA treated group with respect to untreated HPMEC control (Fig. 5C ). In addition, ATP and ADP levels of DHA treated cells remained elevated above those of control cells at 
Inhibition of CD73 by ATP-γS and AOPCP
The effects of nucleotide analogues on CD73 activity for our experimental conditions are summarized in Fig. 6 . The stable ATP analogue ATP-γS dose-dependently inhibited ε-AMP conversion rate by about 14±4 % at 500 nmol/l and 28±8 % at 5 µmol/l concentration in comparison to control (p<0.05, Fig. 6A) . A similar result was observed in HPMEC (data not shown). An even stronger inhibitory effect was obtained for the stable ADP analogue AOPCP, which increased t 50 by 40±4 % to 180±11 % at AOPCP concentrations ranging from 63.5 to HUVEC were incubated with ATP-γS (15 min) or AOPCP (20 min) at concentrations indicated. ε-AMP (5 µmol/l) was added as substrate to assess CD73 enzymatic activity. Mean data ± SE, n≥3 experiments, NS: not significant, *p<0.05; **p<0.005; ***p<0.0001 vs. control. Fig. 6B ). Thus, CD73 activity is highly sensitive to inhibition by ATP-and ADP-analogues in human endothelial cells.
Discussion
The present study demonstrates that DHA exposure of human endothelial cells results in a complex reorganization of extracellular adenine nucleotide metabolism including 1) increased CD73 protein content, 2) decreased CD39 expression associated with decreased catalytic activity, and 3) enhanced cellular adenine nucleotide release. These effects interact on the whole cell level by augmenting extracellular adenine nucleotide concentrations and consecutively decreasing CD73 activity despite an increased CD73 expression. Thus, DHA increases the extracellular adenine nucleotide/adenosine ratio.
After 48 h DHA treatment CD73 surface expression and protein level were increased in human endothelial cells (Fig. 1) . This is in line with a previous study performed in rat endothelial cells [7] . Moreover, our study determines that the increased CD73 activity is strictly related to cell surface expression (Fig. 1A, 1B) . Several mechanisms of CD73 protein content regulation have been described in literature including modulation of plasma membrane fluidity [7] , modulation of lipid raft association with caveolin-1 [22] , regulation of transcription processes [23] , and cholesterol-dependent endocytosis [24] . We have tested whether these concepts apply to the conditions of the current study using RT-PCR to assess the mRNA level and transcriptional regulation of CD73. However, no change in CD73 mRNA level was found (Fig. 1E) . Because DHA was shown to be a ligand for PPAR-γ [25] which may regulate CD73 transcription processes, the PPAR-γ antagonist GW9662 was applied. In line with the negative RT-PCR result, GW9662 had no effect on CD73 protein level (Fig. 1F) . Furthermore, modification of plasma membrane cholesterol either by depletion of cholesterol using filipin and β-methyl-cyclodextrin (MCD) or by enrichment using cholesterol-MCD complex had no impact on CD73 enzyme activity and protein level ( Fig. 2A-C) . Also, cav-1 protein level was unaffected by DHA treatment (Fig. 2D) . It is thus unlikely that previously proposed mechanisms were effective under the conditions of our study.
One previous study performed in isolated cell membrane preparations indicated increased CD73 expression and enzyme activity after DHA treatment [7] . Our study clearly shows that this view needs correction. While our experiments confirm results obtained on the membrane level (Fig. s 1-3) , the new and important finding is that DHA reduced CD73 activity in intact endothelial cells (Fig. 3) . This is in contrast to the conclusion based on experiments using membrane preparations [7] . The present study reveals that the effect of enhanced membrane expression of CD73 in response to DHA is completely set-off by (an) other mechanism(s) on the level of the intact cell.
Ecto-nucleotidases are regulated by a variety of factors including adenine nucleotides. In fact, CD73 is powerfully inhibited by ADP and ATP [16, 26] (Fig. 6A, B) . As shown in Fig.  5 , DHA treatment largely enhanced adenine nucleotide release. The increased extracellular ATP and ADP concentrations blunted CD73 activity under the conditions of the present study (Fig. 4E, F) . We therefore conclude that the increase of CD73 expression on the cell membrane level was counteracted by augmented ATP release from endothelial cells und subsequent block of its hydrolysis. In endothelial cells ATP release has been suggested to occur via P-glycoprotein, CFTR, connexin hemichannels or pannexins [27] [28] [29] although their quantitative contribution is currently unknown.
HUVEC released ATP under control conditions and after DHA treatment at a rate resulting in a nanomolar adenine nucleotide concentration in the cell supernatant. Most notably, the adenine nucleotide fraction was largely elevated in the DHA treated vs. untreated group. While extracellular ATP continuously declined, native ADP level appeared rather constant in the course of the experiment (Fig. 5C) . Although the adenosine level slightly increased over time in the DHA group, it should be stressed that the adenosine fraction was always considerably smaller than those of the adenine nucleotides, in particular the ATP-and ADPfractions.
Thom/Wendel/Deussen: DHA and Extracellular Adenine Nucleotide Metabolism Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry
The metabolic processing of extracellular adenine nucleotides includes a complex cascade of various ecto-enzymes on the cell surface [4, 30, 31] . Key enzymes expressed on human endothelial cells for forward reactions from ATP to ADP to AMP and to adenosine include CD39 and CD73. Backward reactions from AMP to ADP and ATP are catalyzed by ecto-kinases, e.g. adenylate kinase, NDPkinase, ATP synthase. Simultaneous release of ATP and other nucleotides such as ADP and AMP cause additive conformational change of ectokinases pushing the backward reaction to produce more extracellular ATP and ADP. Changes in the ratio of mono-, di-and tri-phosphates may cause feed-forward inhibition of CD73 by the precursors ATP and ADP, respectively [27, 30, 31] . The K i values reported for inhibition of CD73 by ATP are in the low micromolar range and that for inhibition by ADP in the low nanomolar range [15, 16, 32] . The concentrations of ATP and ADP measured in response to DHA treatment were in this range (100-200 nmol/l), while those measured under control conditions were lower (20-50 nmol/l). Thus, quantitative assessment of ATP and ADP concentrations after DHA treatment indicate a role as autocrine inhibitors of CD73 activity in human endothelial cells.
In HPMEC and HUVEC inhibition of CD39 by ARL-67156 resulted in a decrease of CD73 activity, both under control conditions and after DHA treatment (Fig. 4E, F) . This supports the concept that native extracellular adenine nucleotide concentrations regulate activity of CD73. Because CD73 catalytic activity was inhibited following application of ARL-67165 under baseline conditions as well as after DHA treatment, the resulting extracellular ATP or ADP concentrations were likely effective in modulating CD73 activity under the conditions of our study. This effect is supported by a down-regulation of CD39 protein expression and ecto-ADPase enzymatic activity following DHA (Fig. 4A, B) . The results obtained in our reductionist model may help to clarify the mechanisms that mediate the beneficial clinical effects seen after DHA treatment [8, 9, 33] . However, it needs also to be taken into account that the in vivo situation is more complex with e.g. parenchymal cells, platelets, leukocytes and red blood cells representing additional major sources of cellular ATP release. A beneficial effect of an increased adenine nucleotide/adenosine ratio is compatible with an improved endothelial barrier function following block of CD73 [3] . However, it should also be pointed out that a blunted capability of adenosine production by CD73 may be detrimental under conditions of acute lung injury induced by mechanical ventilation [4] or under hypoxic stress in lung [5] or intestinal mucosa [6] . Thus, it is unlikely that the beneficial effects of DHA treatment are caused by adenosine, because its production is rather decreased after DHA (Fig. 3) . Figure 7 summarizes our results. DHA up-regulated CD73 protein level as well as CD73 surface expression. However, CD73 enzymatic activity of human endothelial cells was diminished via feed-forward inhibition by augmented cellular release of ADP and ATP despite increased CD73 surface expression. Because DHA reduced CD39 activity and expression and increased ATP release the extracellular ATP/adenosine ratio was augmented. Because both metabolites act on separate receptors and, hence, separate signal transduction pathways, this concerted action may exert a profound regulatory role. The current study shows that for a comprehensive evaluation of effects seen after DHA substitution the complex regulation of the extracellular adenine nucleotide/ adenosine metabolism must be taken into account rather than single assessment of CD73 expression and activity. 
